# A clear line of sight into FDA data.

> RegLine simplifies regulatory research and monitoring by unifying and standardizing public FDA datasets. Get notified of new records, track relevant changes, investigate company and product histories, and compile regulatory reports with less manual work.

### Stay informed about the brands you follow

**Without RegLine**

Teams manually check separate sources for new records about brands, competitors, and therapeutic areas.

**With RegLine**

Monitor the companies, products, and topics you follow with saved searches and email alerts on your chosen schedule.

### Get to the source and context faster

**Without RegLine**

Investigating a regulatory or MLR question requires finding individual sources and manually assembling the results.

**With RegLine**

Research FDA records in one workflow with related company, product history, and original sources included.

### Trace records across companies and products

**Without RegLine**

Misspellings, recorded-name variations, M&As, and rebrands can leave relevant records outside your search results.

**With RegLine**

Connect records across name variations and verified company relationships to research related history while preserving the original sources.

### Bring the evidence into review

**Without RegLine**

Organizing research for review requires manually copying records, dates, source links, and charts into a consistent format.

**With RegLine**

Prepare for critical decisions with reports that organize relevant FDA sources, dates, context, and charts into a source-backed starting point for your team.

**A real example from RegLine**

## Put company and product history in perspective

Review approvals, labeling, listings, and enforcement events together to see what preceded an event and what changed afterward.

### Pfizer Inc.

Sample of RegLine's data for Pfizer, selected for illustrative purposes.

Jan 1998–Apr 2026

- Approval: 6

- Listing / SPL: 6

- Untitled letter: 8

- Warning letter: 4

- **Jan 1, 1998 · Untitled letter** — Untitled letter - Lipitor — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Dec 21, 1998 · Untitled letter** — Untitled letter - Zyrtec — FDA OPDP enforcement letters

- **Jan 1, 2000 · Untitled letter** — Untitled letter - Trovan — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Jan 1, 2001 · Warning letter** — Warning letter - Lipitor — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Jan 1, 2002 · Untitled letter** — Untitled letter - Geodon — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Jan 1, 2003 · Untitled letter** — Untitled letter - Camptosar — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Apr 13, 2005 · Warning letter** — Warning letter - Zyrtec — FDA OPDP enforcement letters

- **May 6, 2005 · Untitled letter** — Untitled letter - Zoloft — FDA OPDP enforcement letters

- **Apr 16, 2008 · Warning letter** — Warning letter - Viagra — FDA OPDP enforcement letters

- **May 24, 2012 · Warning letter** — Warning letter - EpiPen — FDA OPDP enforcement letters

- **Jun 19, 2012 · Untitled letter** — Untitled letter - Zmax — FDA OPDP enforcement letters

- **Feb 25, 2013 · Listing / SPL** — Listed - ATRACURIUM BESYLATE — FDA drug listing

- **Oct 9, 2019 · Listing / SPL** — Listed - MEROPENEM — FDA drug listing

- **Nov 15, 2019 · Approval** — Approval - ADALIMUMAB-AFZB (761118) — Drugs@FDA

- **Oct 19, 2020 · Listing / SPL** — Listed - ERTAPENEM — FDA drug listing

- **Jun 21, 2021 · Approval** — Approval - DAPTOMYCIN (210282) — Drugs@FDA

- **Jan 24, 2022 · Listing / SPL** — Listed - AZTREONAM — FDA drug listing

- **Jun 10, 2022 · Approval** — Approval - PEMETREXED DITROMETHAMINE (208746) — Drugs@FDA

- **Dec 15, 2022 · Approval** — Approval - BENDAMUSTINE HYDROCHLORIDE (211530) — Drugs@FDA

- **Mar 1, 2023 · Listing / SPL** — Listed - REGADENOSON — FDA drug listing

- **Aug 14, 2023 · Approval** — Approval - ELRANATAMAB-BCMM (761345) — Drugs@FDA

- **Sep 11, 2025 · Approval** — Approval - POTASSIUM PHOSPHATES (217459) — Drugs@FDA

- **Mar 16, 2026 · Listing / SPL** — Listed - DOBUTAMINE IN DEXTROSE — FDA drug listing

- **Apr 8, 2026 · Untitled letter** — Untitled letter - ADCETRIS — FDA OPDP enforcement letters

Routine activity

Label versions and listing records, grouped by quarter.

### Celebrex

Label versions are separate labels for products sharing this brand name, rather than revisions of a single label.

Jan 1998–Nov 2024

- Approval: 1

- Label version: 13

- Listing / SPL: 4

- Untitled letter: 6

- Warning letter: 2

- **Jan 1, 1998 · Untitled letter** — Untitled letter - Celebrex — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Dec 31, 1998 · Approval** — Approval - UPJOHN US 2 LLC (020998) — Drugs@FDA

- **Oct 1, 1999 · Untitled letter** — Untitled letter - Celebrex — FDA OPDP enforcement letters

- **Jan 1, 2000 · Untitled letter** — Untitled letter - Celebrex — FDA OPDP enforcement letters. Source records only the year or month for many letters issued before 2004, so this date may not reflect the original issue date.

- **Apr 6, 2000 · Untitled letter** — Untitled letter - Celebrex, Ambien — FDA OPDP enforcement letters

- **Feb 1, 2001 · Warning letter** — Warning letter - Celebrex — FDA OPDP enforcement letters

- **Feb 2, 2001 · Warning letter** — Warning letter - Celebrex — FDA OPDP enforcement letters

- **Jan 10, 2005 · Untitled letter** — Untitled letter - Celebrex and Bextra — FDA OPDP enforcement letters

- **Apr 2, 2009 · Untitled letter** — Untitled letter - AROMASIN, CADUET, CHANTIX, Detrol LA, LYRICA, CELEBREX — FDA OPDP enforcement letters

- **Jul 10, 2009 · Label version** — Label version 1 - Rebel Distributors Corp. - no product detail on record — FDA Structured Product Labels

- **May 13, 2011 · Label version** — Label version 2 - STAT Rx USA LLC - no product detail on record — FDA Structured Product Labels

- **Jun 6, 2011 · Label version** — Label version 1 - Keltman Pharmaceuticals Inc. - no product detail on record — FDA Structured Product Labels

- **Dec 14, 2011 · Label version** — Label version 3 - H.J. Harkins Company, Inc. - no product detail on record — FDA Structured Product Labels

- **Jan 27, 2012 · Label version** — Label version 3 - STAT Rx USA LLC - no product detail on record — FDA Structured Product Labels

- **Sep 12, 2012 · Label version** — Label version 1 - Aidarex Pharmaceuticals LLC - no product detail on record — FDA Structured Product Labels

- **Nov 7, 2013 · Label version** — Label version 2 - Dispensing Solutions, Inc. - no product detail on record — FDA Structured Product Labels

- **Jul 3, 2014 · Label version** — Label version 2 - Aphena Pharma Solutions - Tennessee, LLC - no product detail on record — FDA Structured Product Labels

- **Aug 20, 2014 · Label version** — Label version 1 - Preferred Pharmaceuticals, Inc. - no product detail on record — FDA Structured Product Labels

- **May 5, 2015 · Label version** — Label version 5 - Physicians Total Care, Inc. - no product detail on record — FDA Structured Product Labels

- **Mar 20, 2017 · Label version** — Label version 3247 - Lake Erie Medical DBA Quality Care Products LLC - no product detail on record — FDA Structured Product Labels

- **Oct 14, 2019 · Label version** — Label version 5 - Direct Rx - no product detail on record — FDA Structured Product Labels

- **Sep 12, 2023 · Listing / SPL** — Listed - VIATRIS SPECIALTY LLC — FDA drug listing

- **Oct 11, 2023 · Listing / SPL** — Listed - VIATRIS SPECIALTY LLC — FDA drug listing

- **Jan 10, 2024 · Listing / SPL** — Listed - VIATRIS SPECIALTY LLC — FDA drug listing

- **Sep 13, 2024 · Listing / SPL** — Listed - VIATRIS SPECIALTY LLC — FDA drug listing

- **Nov 22, 2024 · Label version** — Label version 13 - Viatris Specialty LLC - Capsule — FDA Structured Product Labels

Routine activity

Label versions and listing records, grouped by quarter.

RegLine export from Oct 21, 2026. Use RegLine for current data and original sources. Dates prior to Jan 1, 2004 may not reflect the original issue date.

---

**Across the drug lifecycle**

## Bring relevant FDA history into each phase of your work

Use FDA records to understand the competitive landscape before launch, assess claims and risk communication, and track relevant changes throughout your product’s lifecycle.

### Development & evidence planning

What has FDA challenged in this category?

Research category letters to understand how FDA has addressed claims, comparisons, evidence presentation, and risk communication. Use that context to inform clinical, statistical, and regulatory expertise.

### Launch planning

What should we understand before launch?

Explore products, companies, approval history, and promotional enforcement to build a clear view of the competitive and regulatory landscape.

### Asset development & MLR

Has FDA addressed a similar promotional issue?

Find relevant letters, inspect the original context, and organize records for MLR review during and post launch.

### Launch & in-market monitoring

What has changed since our last review?

Use Sightline to follow new records matching your brands, competitors, and therapeutic areas.

### Label updates & new indications

What context should we revisit as the product evolves?

Review current labeling alongside related approvals, products, and enforcement history when evaluating updated positioning or materials.

### Ongoing brand planning

What should inform our next planning cycle?

Revisit the competitive and enforcement landscape and prepare source-backed reports for planning and review discussions.

Sightline keeps monitoring as your product and competitive priorities evolve.

FDA letters reflect specific circumstances at the time of publication. RegLine supports research and monitoring; it does not replace clinical, statistical, legal, medical, or regulatory judgment or guarantee compliance. Klick RegLine™ is independent of and not endorsed by the FDA.

---

**Built for your work**

## Different responsibilities. A shared need for evidence.

For regulatory, compliance, and commercial professionals at pharma and biotech companies, and the agencies supporting them.

- **Regulatory & compliance** — Find relevant enforcement letters when questions arise in MLR review. Assess the source, publication date, and circumstances before applying the context to a new or in-market asset.

- **Commercial & marketing** — Stay current on FDA records relevant to your brands and competitors. Bring regulatory context into asset development and prepare for more informed review discussions.

- **Life sciences agencies** — Monitor client and competitor brands across portfolios. Research relevant FDA records and bring source-backed context to client recommendations.
